Trial Profile
A Multinational, Multicentre, Randomised, Open-Label, Active-Controlled, 26-Week, 2-Arm, Parallel Group Study to Evaluate the Non-Inferiority of Fixed Combination of Beclomethasone Dipropionate Plus Formoterol Fumarate Plus Glycopyrronium Bromide (CHF 5993) Administered Via Pressurized Metered-dose Inhaler (pMDI) Versus Fixed Combination Of Fluticasone Furoate Plus Vilanterol Administered Via Dry Powder Inhaler (DPI) (Relvar) Plus Tiotropium Bromide (Spiriva) for the Treatment of Patients With Chronic Obstructive Pulmonary Disease
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Beclometasone/formoterol/glycopyrrolate (Primary) ; Tiotropium bromide; Vilanterol/fluticasone furoate
- Indications Chronic obstructive pulmonary disease
- Focus Registrational; Therapeutic Use
- Acronyms Tristar
- Sponsors Chiesi Farmaceutici
- 19 Jan 2017 Status changed from active, no longer recruiting to completed.
- 03 Oct 2016 Status changed from recruiting to active, no longer recruiting.
- 30 Mar 2015 New trial record